Current Oncology Reports最新文献

{"title":"Medical Management of Tenosynovial Giant Cell Tumor.","authors":"Emanuela Palmerini, Jonathan C Trent, Francis John Hornicek","doi":"10.1007/s11912-025-01679-x","DOIUrl":"10.1007/s11912-025-01679-x","url":null,"abstract":"<p><strong>Purpose of review: </strong>Diffuse tenosynovial giant cell tumor (D-TGCT) is a benign neoplasm with locally aggressive potential of the synovium, bursae, and tendon sheaths. This review summarizes the current treatment landscape for D-TGCT, with a focus on systemic therapies.</p><p><strong>Recent findings: </strong>Surgery is the primary treatment option for tenosynovial giant cell tumor (TGCT), but there is a high risk of recurrence and associated morbidity, particularly for patients with advanced D-TGCT. Systemic therapies targeting the colony-stimulating factor 1 receptor (CSF1R) have resulted in positive tumor response, improved function, and decreased symptoms. For an alternative to surgery, the CSF1R inhibitors pexidartinib and vimseltinib are approved in the United States for TGCT, and other CSF1R inhibitors are in clinical development. CSF1R inhibitors represent a significant evolution in therapeutic strategies for D-TGCT. The potential risks and benefits of available treatments should be carefully considered in collaboration with a bone tumor-experienced, multidisciplinary team to determine the best course of care. Increased D-TGCT awareness and support through patient advocacy groups have helped to reshape the patient journey.</p>","PeriodicalId":10861,"journal":{"name":"Current Oncology Reports","volume":" ","pages":"844-855"},"PeriodicalIF":5.0,"publicationDate":"2025-07-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://www.ncbi.nlm.nih.gov/pmc/articles/PMC12328534/pdf/","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"144109861","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":2,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"State-of-the-art in Metastatic Uveal Melanoma Treatment: A 2025 Update : How to treat Metastatic Uveal Melanoma in 2025.","authors":"Dimitrios C Ziogas, Dimitra Foteinou, Charalampos Theocharopoulos, Anastasios Martinos, Dioni-Pinelopi Petsiou, Amalia Anastasopoulou, Helen Gogas","doi":"10.1007/s11912-025-01684-0","DOIUrl":"10.1007/s11912-025-01684-0","url":null,"abstract":"<p><strong>Purpose of review: </strong>Uveal melanoma (UM) is the most common intraocular malignancy in adults, representing a rare but aggressive melanoma subtype with a distinct molecular landscape, unique metastatic behavior and limited therapeutic options in the metastatic setting. This review provides an in-depth analysis of the latest evidence on the evolving treatment landscape of metastatic UM.</p><p><strong>Recent findings: </strong>For liver-only metastatic disease, locoregional therapies provide significant benefit compared to systemic therapies. The recent approval of tebentafusp-tebn, a bispecific gp100 peptide-HLA-directed CD3 T-cell engager, marks a pivotal advancement for HLA-A*02:01-positive patients with unresectable/metastatic UM, demonstrating a clinically significant survival benefit. Several clinical studies are currently active, examining emerging locoregional and systemic treatments for metastatic UM, with promising early data. Despite effective local disease control through radiotherapy and enucleation, approximately 50% of patients develop metastatic disease, predominantly in the liver, with a median survival of less than one year. The approval of tebentafusp represents a landmark achievement in UM treatment, while promising experimental combinations have demonstrated clinical utility in late phase clinical trials, offering hope for further improvement in patient survival.</p>","PeriodicalId":10861,"journal":{"name":"Current Oncology Reports","volume":" ","pages":"803-821"},"PeriodicalIF":5.0,"publicationDate":"2025-07-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://www.ncbi.nlm.nih.gov/pmc/articles/PMC12328531/pdf/","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"144085969","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":2,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"Linking Hyperuricemia to Cancer: Emerging Evidence on Risk and Progression.","authors":"Lingyun Zhao, Ruihong Guo, Ziming Zhao, Jue Wang, Zhonghan Lou, Jianfeng Bao, Wei Zheng, Qiang Wang, Liang Qiao, Yun Ye, Hiu Yee Kwan, Hua Zhou, Qibiao Wu, Keyang Xu","doi":"10.1007/s11912-025-01677-z","DOIUrl":"10.1007/s11912-025-01677-z","url":null,"abstract":"<p><strong>Purpose of review: </strong>Metabolic disorders significantly contribute to cancer burden globally. Uric acid (UA), a recognized metabolic risk factor linked to gout, also promotes insulin resistance, fatty liver, inflammation, and carcinogenesis. This systematic review evaluates UA's dual role in cancer, synthesizing epidemiological, mechanistic, and clinical evidence to clarify its potential as a therapeutic target.</p><p><strong>Recent findings: </strong>The research of UA on cancer development mainly focuses on a clinical observational study, with limited molecular mechanism exploration. The associations between UA and cancer risk remain controversial, as sometimes the antioxidant, anti-inflammatory and immune-enhancing properties of UA are presented. There is lacking a systematic and updated review for summarizing the role of hyperuricemia on cancer risk and progression. The precise mechanism of UA in either enhancing or inhibiting cancer progression remains uncertain. Serum uric acid (SUA) exhibits paradoxical roles in cancer, with its effects varying by tumor type, concentration, gender, and disease stage. While UA predominantly drives tumorigenesis in most cancers, it shows protective effects in specific malignancies such as soft-tissue sarcoma and laryngeal squamous cell carcinoma, potentially through antioxidant activity at lower concentrations. Mechanistically, UA highly participate in the cancer risk and progression through reactive oxygen species (ROS) generation, disrupting T cell activation and dendritic cell maturation, exacerbating insulin resistance, and driving xanthine oxidoreductase (XOR) expression during the process of wound healing. Emerging clinical and mechanistic evidence highlights its oncogenic potential, underscoring the need for large-scale randomized controlled trials and cohort studies to clarify the relationship between hyperuricemia and cancer progression. Future research should prioritize exploring anti-UA therapies for cancer treatment, developing advanced animal models to dissect UA's mechanisms, and integrating diverse genomic datasets to unravel its context-dependent roles. Addressing these gaps will advance targeted strategies to leverage UA biology in cancer management.</p>","PeriodicalId":10861,"journal":{"name":"Current Oncology Reports","volume":" ","pages":"703-716"},"PeriodicalIF":5.0,"publicationDate":"2025-06-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"143967494","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":2,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"Social Needs in Cancer Survivors: A Scoping Review and Future Directions.","authors":"Tess Thompson, Meredith Doherty, Julie Berrett-Abebe, Chelsea Brown, Emily Hallgren, Sam Kirk, Rory Weal, Krutika Chauhan, Tamara J Cadet","doi":"10.1007/s11912-025-01664-4","DOIUrl":"10.1007/s11912-025-01664-4","url":null,"abstract":"<p><strong>Purpose of review: </strong>We conducted a scoping review to determine what is known about the prevalence and consequences of unmet social needs in U.S. cancer survivors, what screening tools are used to assess these needs, and what interventions have been developed to meet the needs of cancer survivors.  RECENT FINDINGS: We identified records from six databases. Inclusion criteria were peer-reviewed journal articles in English with empirical data from U.S.-based samples of people diagnosed with cancer as adults and assessing one of the following modifiable, individual-level needs commonly included in clinical screening: food insecurity, financial hardship, utility assistance, employment, housing, transportation, or personal safety. The search yielded 11,074 abstracts; 543 records underwent full-text review, and 189 were retained for data extraction. Most studies were quantitative and observational (88%), not based on theory (88%), and cross-sectional (87%). The majority addressed financial toxicity, commonly evaluated using the COmprehensive Score for financial Toxicity (COST). Fewer studies focused on food insecurity, transportation barriers, housing concerns, personal safety, or utility assistance. Included studies reported that financial toxicity and other social needs were negatively associated with health-related quality of life, mental health, and adherence to care.  Financial toxicity is now a well-established challenge for cancer patients, which suggests financial interventions may be widely beneficial. Future work is needed to develop a fuller picture of cancer survivors' other social needs, and to understand and address the impact of unmet social needs on clinical, health, and psychosocial outcomes.</p>","PeriodicalId":10861,"journal":{"name":"Current Oncology Reports","volume":" ","pages":"717-733"},"PeriodicalIF":5.0,"publicationDate":"2025-06-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://www.ncbi.nlm.nih.gov/pmc/articles/PMC12451746/pdf/","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"143967708","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":2,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"Effectiveness and Safety of Immune Checkpoint Inhibitors in Colorectal Cancer: A Systematic Review of Real-World Studies.","authors":"Leping Kong, Chin Hang Yiu, Christine Y Lu","doi":"10.1007/s11912-025-01676-0","DOIUrl":"10.1007/s11912-025-01676-0","url":null,"abstract":"<p><strong>Purpose of review: </strong>Immune checkpoint inhibitors (ICIs) have demonstrated significant efficacy in the treatment of colorectal cancer (CRC). However, most evidence has come from clinical trials with strict eligibility criteria. Understanding real-world effectiveness and safety of ICIs in CRC is important to guide routine clinical practice across diverse populations.</p><p><strong>Recent findings: </strong>A systematic review following PRISMA guidelines was conducted to identify observational studies evaluating ICI-based regimens compared to conventional or combination therapies in patients with CRC. Three databases (MEDLINE, Embase, and Scopus) were searched from inception through March 15, 2025. Eligible studies reported at least one efficacy outcome (e.g., progression-free survival [PFS], overall survival [OS], etc.) and/or safety outcome (e.g., adverse events) among real-world populations with CRC treated with ICIs. Study quality was assessed using the Newcastle-Ottawa Scale, and a narrative synthesis was performed to summarize the key findings. Eleven real-world studies met the inclusion criteria, encompassing data from 2,049 patients. In MSI-H/dMMR metastatic CRC, real-world findings aligned with the survival benefits observed in clinical trials, demonstrating improved PFS and OS compared to conventional therapies. For MSS/pMMR metastatic CRC, combining ICIs with other agents (e.g., tyrosine kinase inhibitors or chemotherapy) showed improvements but yielded conflicting results. Overall, the safety profiles were comparable to conventional therapies, with treatment-related adverse events occurring at similar rates. Real-world evidence supports the efficacy of ICI monotherapy in MSI-H/dMMR metastatic CRC and suggests potential benefits of ICI-based combination therapies in MSS/pMMR metastatic CRC. However, most of the data are derived from small, single-center cohorts, which limit their generalizability. Further multi-center studies are needed, especially to assess the efficacy of ICI-based combination therapies in the broader CRC population.</p>","PeriodicalId":10861,"journal":{"name":"Current Oncology Reports","volume":" ","pages":"687-702"},"PeriodicalIF":5.0,"publicationDate":"2025-06-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://www.ncbi.nlm.nih.gov/pmc/articles/PMC12227369/pdf/","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"143983599","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":2,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"The Role of Transplant for Philadelphia-positive B-cell Acute Lymphoblastic Leukemia in 2025.","authors":"Vaibhav Agrawal, Paul Koller, Anthony Stein, Vinod Pullarkat, Ibrahim Aldoss","doi":"10.1007/s11912-025-01683-1","DOIUrl":"10.1007/s11912-025-01683-1","url":null,"abstract":"<p><strong>Purpose of review: </strong>This review expands upon the evolving role of allo-HSCT, integrating current clinical evidence, emerging therapies, and novel risk-adapted strategies for managing adult with Ph + ALL in the contemporary era.</p><p><strong>Recent findings: </strong>Philadelphia chromosome-positive (Ph +) acute lymphoblastic leukemia (ALL) is the most common genetically defined subtype of B-cell ALL. The treatment of Ph + ALL has witnessed significant advancements over the past two decades following the introduction of BCR::ABL1 tyrosine kinase inhibitors (TKIs). Allogeneic hematopoietic stem cell transplantation (allo-HSCT) has long been a cornerstone treatment in adult patients with Ph + ALL, offering the most reliable disease curative potential, and the early use of TKIs has led to successfully transplanting more patients. Lately, the early introduction of more potent TKIs and blinatumomab have further reshaped the frontline treatment paradigm of Ph + ALL and resulted into improved outcomes even in the absence of transplant consolidation. Simultaneously, our ability to stratify disease risk has greatly enhanced with the advent of ultrasensitive measurable residual disease (MRD) assessment tools and the utilization of comprehensive disease molecular profiling, and thus, identifying lower risk patients who can be cured with non-transplant approaches. With evolving treatment options for Ph + ALL, the historical notion that allo-HSCT in first complete remission is essential to cure all adult patients with Ph + ALL is being challenged and the benefit of consolidation with transplant may extend to certain patient populations.</p>","PeriodicalId":10861,"journal":{"name":"Current Oncology Reports","volume":" ","pages":"748-760"},"PeriodicalIF":4.7,"publicationDate":"2025-06-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"143967927","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":2,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"Carbon Ion Radiotherapy in the Head and Neck Cancers Treatment and its Potential Role in Personalized Treatment Approach- A Review of the Current Knowledge.","authors":"Katarzyna Pazdro-Zastawny, Joanna Krajewska, Marta Zastawny, Karolina Dorobisz","doi":"10.1007/s11912-025-01673-3","DOIUrl":"10.1007/s11912-025-01673-3","url":null,"abstract":"<p><strong>Purpose of review: </strong>Head and neck cancer (HNC) is a complex, heterogeneous group of malignancies. In treatment a combined modality therapy with surgery, radiotherapy and chemotherapy is usually advised. The use of charged particles was a breakthrough in radiation oncology and allowed the initiation of cancer treatment with high-precision. The purpose of the work is to discuss the role of carbon ion radiotherapy in the treatment of head and neck cancers.</p><p><strong>Recent findings: </strong>Heavy ions such as carbon have more favorable physical and radiobiological properties than photons. The unique properties of carbon ions enable radiotherapy with dose escalation to tumors, while reducing both, radiation dose to adjacent normal tissues and radiation area. Considering its exceptional features, carbon ion radiotherapy offers promising results with acceptable toxicity regarding treatment of uncommon and rare malignancies, especially treated for a recurrent disease. HNC patients with adenoid cystic carcinoma and mucosal melanoma of the head and neck, which are considered to be radiation resistant, should benefit more from carbon ion radiotherapy than proton beam therapy or conventional photon radiotherapy. Also selected patients with other head and neck malignancies can benefit form carbon ion radiotherapy including advanced salivary gland cancer and nasopharyngeal cancer patients. Carbon ion radiotherapy offers better dose distributions, higher tumor doses, and an increased odds of local control and prolonged survival. Carbon ion radiotherapy represents a promising alternative to conventional photon RT or even proton beam therapy especially in treatment of radioresistant tumors situated close to critical organs.</p>","PeriodicalId":10861,"journal":{"name":"Current Oncology Reports","volume":" ","pages":"657-668"},"PeriodicalIF":4.7,"publicationDate":"2025-06-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"143962898","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":2,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"The Evolving Role of PSMA-PET/CT in Prostate Cancer Management: an Umbrella Review of Diagnostic Restaging, Therapeutic Redirection, and Survival Impact.","authors":"Licheng Wang, Lizhun Wang, Xin'an Wang, Denglong Wu","doi":"10.1007/s11912-025-01682-2","DOIUrl":"10.1007/s11912-025-01682-2","url":null,"abstract":"<p><strong>Purpose of review: </strong>This review explores the clinical applications of PSMA-PET/CT in patients with intermediate to high-risk prostate cancer, focusing on its role in diagnostic reassessment, therapeutic redirection, and potential survival benefits. By evaluating its translational pathway, we aim to provide a structured analysis of its impact on patient management and treatment outcomes.</p><p><strong>Recent findings: </strong>Prostate cancer remains a significant health challenge, and advancements in imaging techniques such as PSMA-PET/CT have shown promise in improving diagnostic accuracy and guiding treatment decisions. Emerging evidence highlights its superior sensitivity and specificity compared to conventional imaging, facilitating better staging, detection of metastases, and therapy selection. However, challenges persist in standardizing clinical applications, integrating findings into treatment guidelines, and addressing economic considerations. This review synthesizes the latest research findings and cost-effectiveness analyses to establish a comprehensive translational framework for PSMA-PET/CT in prostate cancer management. By consolidating diverse evidence, we aim to provide the medical community with clearer insights into its clinical utility, address ongoing controversies, and propose strategies to minimize treatment risks. The conclusions drawn from this study aspire to refine treatment protocols and enhance clinical outcomes for patients with this prevalent malignancy.</p>","PeriodicalId":10861,"journal":{"name":"Current Oncology Reports","volume":" ","pages":"774-787"},"PeriodicalIF":5.0,"publicationDate":"2025-06-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://www.ncbi.nlm.nih.gov/pmc/articles/PMC12227496/pdf/","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"143987215","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":2,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"Targeting Lung Cancer with Precision: The ADC Therapeutic Revolution.","authors":"Reema Kamal Tawfiq, Guilherme Sacchi de Camargo Correia, Shenduo Li, Yujie Zhao, Yanyan Lou, Rami Manochakian","doi":"10.1007/s11912-025-01655-5","DOIUrl":"10.1007/s11912-025-01655-5","url":null,"abstract":"<p><strong>Purpose of review: </strong>This review explores the evolving role of antibody-drug conjugates (ADCs) in lung cancer treatment, with a focus on their application in non-small cell lung cancer (NSCLC) and small cell lung cancer (SCLC). It highlights advancements in ADC design, mechanisms of action, and key outcomes from recent clinical trials.</p><p><strong>Recent findings: </strong>ADCs have introduced a new level of precision in oncology by targeting tumor-specific antigens such as HER2, HER3, and TROP-2. Recent clinical trials of agents like trastuzumab deruxtecan, datopotamab deruxtecan, and sacituzumab govitecan have demonstrated meaningful objective response rates and manageable toxicity, offering hope for patients with advanced NSCLC and SCLC. ADCs are transforming the treatment landscape for lung cancer, offering a blend of targeted delivery and potent therapeutic effects. With ongoing efforts to improve safety, efficacy, and antigen targeting, ADCs have the potential to become a cornerstone of lung cancer therapy and pave the way for innovative multimodal approaches in the future.</p>","PeriodicalId":10861,"journal":{"name":"Current Oncology Reports","volume":" ","pages":"669-686"},"PeriodicalIF":4.7,"publicationDate":"2025-06-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"143965161","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":2,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"Liquid Biopsy in Hepatocellular Carcinoma: ctDNA as a Potential Biomarker for Diagnosis and Prognosis.","authors":"William Yang, Romario Nguyen, Fatema Safri, Muhammad J A Shiddiky, Majid E Warkiani, Jacob George, Liang Qiao","doi":"10.1007/s11912-025-01681-3","DOIUrl":"10.1007/s11912-025-01681-3","url":null,"abstract":"<p><strong>Purpose of review: </strong>Hepatocellular carcinoma (HCC) is a leading cause of cancer-related mortality worldwide, with rising incidence and mortality. Early-stage HCC is often asymptomatic, and the lack of reliable early diagnostic markers leads to late-stage diagnosis with limited treatment options. Current treatment relies on tumour staging and patient status, but accurate staging requires invasive procedures that fail to capture tumour heterogeneity and progression. There is an urgent need for less invasive diagnostic strategies, such as liquid biopsy technologies, which allow for repeated sampling and real-time analysis of tumour dynamics. Liquid biopsies, including circulating tumour cells (CTCs) and circulating tumour DNA (ctDNA), offer the potential to monitor recurrence, metastasis, and treatment responses, potentially transforming HCC clinical management by enabling earlier intervention and personalised treatment strategies.</p><p><strong>Recent findings: </strong>Recent studies emphasise the potential of ctDNA as a non-invasive biomarker by targeting DNA methylation for early HCC detection, enabling timely intervention and personalised treatment to improve patient outcomes. Comparative analyses have shown that ctDNA mutation testing outperforms alpha-fetoprotein (AFP), with a sensitivity of 85% and a specificity of 92%, compared to 60% sensitivity and 80% specificity for AFP. Additionally, profiling the ctDNA mutation landscape of 100 HCC patients has identified recurrent mutations in genes such as TP53, CTNNB1, and AXIN1. ctDNA appears to be a promising non-invasive biomarker in the clinical management of HCC patients, with the sensitivity and specificity improving by 41.67% and 15% respectively. The ctDNA mutations, particularly those targeting DNA methylation, highlight great potential for precision medicine, critical for early diagnosis and prognosis of HCC.</p>","PeriodicalId":10861,"journal":{"name":"Current Oncology Reports","volume":" ","pages":"791-802"},"PeriodicalIF":4.7,"publicationDate":"2025-06-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://www.ncbi.nlm.nih.gov/pmc/articles/PMC12227495/pdf/","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"143986741","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":2,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}